{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Clear+Cell+Renal+Cell+Carcinoma&page=4",
    "query": {
      "condition": "Recurrent Clear Cell Renal Cell Carcinoma",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 195,
    "total_pages": 20,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Clear+Cell+Renal+Cell+Carcinoma&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Clear+Cell+Renal+Cell+Carcinoma&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-11T16:43:08.517Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00003928",
      "title": "Gemcitabine Plus Cisplatin in Treating Patients With Metastatic Kidney Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "1999-01",
      "completion_date": "2006-04",
      "has_results": false,
      "last_update_posted_date": "2010-06-11",
      "last_synced_at": "2026-10-11T16:43:08.517Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003928"
    },
    {
      "nct_id": "NCT00003585",
      "title": "Biological Therapy Plus Chemotherapy in Treating Patients With Metastatic or Recurrent Kidney Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "recombinant interferon alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "isotretinoin",
          "type": "DRUG"
        },
        {
          "name": "surgical procedure",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of New Mexico",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 35,
      "start_date": "1996-08",
      "completion_date": "2002-08",
      "has_results": false,
      "last_update_posted_date": "2013-12-10",
      "last_synced_at": "2026-10-11T16:43:08.517Z",
      "location_count": 1,
      "location_summary": "Albuquerque, New Mexico",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003585"
    },
    {
      "nct_id": "NCT04370509",
      "title": "Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Clear Cell Renal Cell Carcinoma",
        "Recurrent Clear Cell Renal Cell Carcinoma",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8",
        "Clear Cell Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Axitinib (VEGF-TKI)",
          "type": "DRUG"
        },
        {
          "name": "Cytoreductive Nephrectomy (CN)",
          "type": "PROCEDURE"
        },
        {
          "name": "Metastasectomy (MET)",
          "type": "PROCEDURE"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2021-02-09",
      "completion_date": "2025-02-28",
      "has_results": true,
      "last_update_posted_date": "2025-11-19",
      "last_synced_at": "2026-10-11T16:43:08.517Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04370509"
    },
    {
      "nct_id": "NCT00003091",
      "title": "High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Cancer",
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "recombinant interferon alfa",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Hoag Memorial Hospital Presbyterian",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "1996-01",
      "completion_date": "2000-01",
      "has_results": false,
      "last_update_posted_date": "2011-05-12",
      "last_synced_at": "2026-10-11T16:43:08.517Z",
      "location_count": 4,
      "location_summary": "Newport Beach, California • Bloomington, Indiana • Knoxville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Bloomington",
          "state": "Indiana"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        },
        {
          "city": "Bryan",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003091"
    },
    {
      "nct_id": "NCT00030342",
      "title": "Biological Therapy and Chemotherapy in Treating Patients With Metastatic Kidney Cancer or Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "recombinant interferon alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic autologous lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "fluorouracil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "St. Luke's Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2001-11",
      "completion_date": "2008-01",
      "has_results": false,
      "last_update_posted_date": "2013-06-26",
      "last_synced_at": "2026-10-11T16:43:08.517Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00030342"
    },
    {
      "nct_id": "NCT00093522",
      "title": "Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "autologous tumor cell vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "keyhole limpet hemocyanin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic autologous dendritic cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "conventional surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "St. Luke's Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2004-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-12-19",
      "last_synced_at": "2026-10-11T16:43:08.517Z",
      "location_count": 2,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00093522"
    },
    {
      "nct_id": "NCT05597839",
      "title": "Study of DF9001 in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult"
      ],
      "interventions": [
        {
          "name": "DF9001",
          "type": "DRUG"
        },
        {
          "name": "KEYTRUDA® (pembrolizumab)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dragonfly Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2022-11-15",
      "completion_date": "2025-08-15",
      "has_results": false,
      "last_update_posted_date": "2025-10-29",
      "last_synced_at": "2026-10-11T16:43:08.517Z",
      "location_count": 17,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Irvine, California + 14 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05597839"
    },
    {
      "nct_id": "NCT07227402",
      "title": "A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Belzutifan",
          "type": "DRUG"
        },
        {
          "name": "Zanzalintinib",
          "type": "DRUG"
        },
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 904,
      "start_date": "2025-11-26",
      "completion_date": "2032-02-27",
      "has_results": false,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-10-11T16:43:08.517Z",
      "location_count": 10,
      "location_summary": "Anchorage, Alaska • Fullerton, California • Los Angeles, California + 6 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Westbrook",
          "state": "Maine"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07227402"
    },
    {
      "nct_id": "NCT00729053",
      "title": "Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "IMO-2055",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Idera Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 92,
      "start_date": "2004-06",
      "completion_date": "2008-11",
      "has_results": true,
      "last_update_posted_date": "2018-06-12",
      "last_synced_at": "2026-10-11T16:43:08.517Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00729053"
    },
    {
      "nct_id": "NCT05119335",
      "title": "A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "ccRCC",
        "Clear Cell Renal Cell Carcinoma",
        "Kidney Cancer",
        "Kidney Neoplasms",
        "Renal Cancer",
        "Renal Neoplasms",
        "Recurrent Renal Cell Carcinoma",
        "Metastatic Renal Cell Carcinoma",
        "Refractory Renal Cell Carcinoma",
        "Advanced Renal Cell Carcinoma",
        "Hypoxia",
        "Renal Cell Carcinoma",
        "Hypoxia Inducible Factor (HIF)",
        "HIF2α Inhibitor",
        "Hypoxia Inducible Factor 2 Alpha (HIF-2 Alpha)",
        "Hypoxia Inducible Factor 2α (HIF-2α)",
        "Clear Cell"
      ],
      "interventions": [
        {
          "name": "Oral NKT2152",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NiKang Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2021-10-26",
      "completion_date": "2025-09-30",
      "has_results": false,
      "last_update_posted_date": "2025-11-12",
      "last_synced_at": "2026-10-11T16:43:08.517Z",
      "location_count": 13,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 10 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05119335"
    }
  ]
}